Anti-diabetic effects of benfotiamine on an animal model of type 2 diabetes mellitus / 대한수의학회지
Korean Journal of Veterinary Research
;
: 21-26, 2014.
Artículo
en Inglés
| WPRIM
| ID: wpr-65255
ABSTRACT
Although benfotiamine has various beneficial anti-diabetic effects, the detailed mechanisms underlying the impact of this compound on the insulin signaling pathway are still unclear. In the present study, we evaluated the effects of benfotiamine on the hepatic insulin signaling pathway in Otsuka Long-Evans Tokushima Fatty (OLETF) rats, which are a type 2 diabetes mellitus model. OLETF rats treated with benfotiamine showed decreased body weight gain and reduced adipose tissue weight. In addition, blood glucose levels were lower in OLETF rats treated with benfotiamine. Following treatment with benfotiamine, the levels of Akt phosphorylation (S473/T308) in the OLETF groups increased significantly compared to the OLETF control group so that they were almost identical to the levels observed in the control group. Moreover, benfotiamine restored the phosphorylation levels of both glycogen synthase kinase (GSK)-3alpha/beta (S21, S9) and glycogen synthase (GS; S641) in OLETF rats to nearly the same levels observed in the control group. Overall, these results suggest that benfotiamine can potentially attenuate type 2 diabetes mellitus in OLETF rats by restoring insulin sensitivity through upregulation of Akt phosphorylation and activation of two downstream signaling molecules, GSK-3alpha/beta and GS, thereby reducing blood glucose levels through glycogen synthesis.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Asunto principal:
Fosforilación
/
Glucemia
/
Peso Corporal
/
Resistencia a la Insulina
/
Regulación hacia Arriba
/
Tejido Adiposo
/
Glucógeno Sintasa
/
Ratas Endogámicas OLETF
/
Modelos Animales
/
Glucógeno Sintasa Quinasas
Límite:
Animales
Idioma:
Inglés
Revista:
Korean Journal of Veterinary Research
Año:
2014
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS